CT-based follow-up following radiotherapy or radiochemotherapy for locally advanced head and neck cancer; outcome and development of a prognostic model for regional control by Nevens, Daan et al.
BJR © 2016 The Authors. Published by the British Institute of Radiology
Received:
3 June 2016
Revised:
14 September 2016
Accepted:
29 September 2016
http://dx.doi.org/10.1259/bjr.20160492
Cite this article as:
Nevens D, Vantomme O, Laenen A, Hermans R, Nuyts S. CT-based follow-up following radiotherapy or radiochemotherapy for locally
advanced head and neck cancer; outcome and development of a prognostic model for regional control. Br J Radiol 2016; 89: 20160492.
FULL PAPER
CT-based follow-up following radiotherapy or
radiochemotherapy for locally advanced head and neck
cancer; outcome and development of a prognostic model
for regional control
1DAAN NEVENS, MD, 1OLIVIER VANTOMME, MD, 2ANNOUSCHKA LAENEN, PhD, 3ROBERT HERMANS, MD, PhD and
1SANDRA NUYTS, MD, PhD
1Department of Radiation Oncology, KU Leuven—University of Leuven, University Hospitals Leuven, Leuven, Belgium
2Leuven Biostatistics and Statistical Bioinformatics Centre, University of Leuven, Leuven, Belgium
3Department of Radiology, KU Leuven—University of Leuven, University Hospitals Leuven, Leuven, Belgium
Address correspondence to: Prof. Dr. Sandra Nuyts
E-mail: Sandra.nuyts@uzleuven.be
Objective: The purpose of this study was to make
a prognostic model for regional relapse in head and neck
cancer using clinical and CT parameters.
Methods: 183 patients with lymph node-positive head and
neck cancer were treated between 2002 and 2012 with
radiotherapy or concurrent chemoradiotherapy. CT stud-
ies pre- and post-treatment were reviewed for lymph
node size and the presence of necrosis, extracapsular
spread (ECS) and calcifications. For every patient, cor-
relations with 3-year regional control (RC), metastasis-
free survival (MFS), disease-free survival (DFS) and
overall survival (OS) were made.
Results: 3-year outcome rates were as follows: local
control of 84%, RC of 80%, MFS of 74%, DFS of 61% and
OS of 63%. Pre-treatment nodal size and the presence of
necrosis were associated with a poorer outcome. This
was also the case for post-treatment lymph node size, the
presence of necrosis and ECS. We developed a CT-based
prognostic model for RC with an area under the curve of
0.78 (95% confidence interval 0.63; 0.85).
Conclusion: We reached a good outcome in our patient
cohort using a CT-based follow-up approach. A CT-based
model was developed, which can aid in predicting RC.
Advances in knowledge: A prognostic model is pro-
posed, which can aid in predicting RC and the necessity
for post-radiotherapy neck dissection using clinical
parameters and parameters derived from the post-
treatment CT study. This is the first article to propose
a prognostic model for regional relapse in head and neck
cancer based on these parameters.
INTRODUCTION
Head and neck cancer encompasses a large number of
tumour entities originating from subsites such as the nasal
cavity, nasopharynx, oral cavity, oropharynx, larynx, hy-
popharynx and salivary glands. The majority of these
tumours are squamous cell carcinoma.1 Head and neck
cancer is the ﬁfth most common cancer worldwide. In the
USA, about 55,070 new cases were estimated for the
year 2014.2
Approximately 60–80% of patients present with locoregion-
ally advanced disease at the time of diagnosis. Radio(chemo)
therapy has become the standard of care for this subset of
patients.3,4 Overall survival (OS) after radio(chemo)therapy
ranges between 50 and 60% after 5 years of follow-up. Local
recurrence and/or regional recurrence (RR) is the most fre-
quent form of therapy failure after radio(chemo)therapy,
while failure due to metastasis is much less common.5,6
Close follow-up of the neck after radio(chemo)therapy in
this patient group is therefore very important. At our centre,
the need for neck dissection after radiotherapy is determined
based on the nodal response on the post-radiotherapy CT
study 4 months after radiotherapy. Only patients who show
suspicion of residual disease undergo a subsequent salvage
neck dissection. Owing to the increased risk of potentially
severe post-operative complications such as wound
infection, ﬁstulae, skin ﬂap necrosis, pneumonia and
pulmonary embolism, we aimed to limit the amount of
unnecessary neck dissection.7,8 Moreover, surgery exacer-
bates chronic effects of radiation such as subdermal ﬁbrosis,
neck stiffness and shoulder dysfunction.9
Management of the neck following radiotherapy or
radio(chemo)therapy has evolved over the past decades
and has been a ﬁeld of debate. Traditionally, patients with
advanced neck disease underwent planned neck dissection after
radiotherapy.7 In the 1990s, however, several institutes demon-
strated low rates of neck failure in patients who had complete
clinical response by physical examination and were not submitted
to neck dissection.10,11 Nowadays, considerable variability
exists in the follow-up of head and neck cancer. Both CT and
positron emission tomography (PET) studies are being used for
response evaluation.12–14 Data on the use of CT are, however,
scarce. The aim of this study was to report the outcome of a
CT-based follow-up of the neck after radiotherapy or radio-
chemotherapy for head and neck cancer and to investigate
whether a prognostic model can be made to determine the risk
of RR for every individual patient.
METHODS AND MATERIALS
Inclusion criteria and end points
Between January 2002 and December 2012, 183 consecutive
patients with nodal positive squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx or larynx were treated with radio
(chemo)therapy or radiotherapy. Inclusion and exclusion criteria
are speciﬁed in Figure 1. Patients were included by review of patient
ﬁles. The patients were assessed clinically weekly during and after
treatment until acute side effects regressed and every 2 months for
the ﬁrst 2 years, every 3 months for the third year, every 4 months
for the fourth, every 6 months the ﬁfth year and then yearly.
Follow-up with CT study was carried out 4 months after com-
pletion of radiotherapy in all patients. Only those with suspicion
of residual neck disease underwent subsequent neck dissection.
In equivocal cases, follow-up CT studies were carried out,
omitting a neck dissection in non-evolving situations.
The primary end point of this study is 3-year RR. Secondary end
points are 3-year local control (LC), metastasis-free survival
(MFS), OS and disease-free survival (DFS).
Analysis of the CT imaging data
CT studies prior and after radio(chemo)therapy were reviewed
for all included patients. All CT studies were performed using
multidetector spiral CT. An iodinated contrast agent was injec-
ted in most patients; 100ml at a rate of 1–1.5ml s21. Scanning
was started 80–100 s after the start of the contrast agent in-
jection. The native CT images were acquired with a slice
thickness of 0.6–0.75mm and reformatted for display with
a slice thickness of 3mm.
All CT studies were analyzed by a single observer under the
supervision of both a radiologist and a radiation oncologist
specialized in head and neck cancer. Volumes and diameters of
the lymph nodes were calculated using the Impax Volume
Viewing 3D software from Agfa Healthcare.
We scored nodal volume, largest axial diameter, necrosis,
extracapsular spread (ECS) and the presence of calciﬁcations in
all pathological lymph nodes in our patient population both on
the pre- and post-treatment CT study.
The scoring of the CT images was carried out blinded to patient
outcome and blinded to follow-up imaging.
Statistical analysis
Description of the time-to-event outcomes (LC, MFS, DFS
and OS) of the patient cohort was based on Kaplan–Meier
estimates. Predictors for time-to-event outcomes were ana-
lyzed by Cox regression models, and results were presented as
hazard ratios (HRs) with 95% conﬁdence intervals (CIs).
Predictors for binary outcomes (RR) were analyzed by logistic
regression models, and results were presented as odds ratios
(ORs) with 95% CIs. Analyses have been performed using
SAS® software v. 9.4 (SAS Institute Inc., Cary, NC) of the SAS
System for Windows.
We correlated age, gender, tumour (T) and nodal (N) stage,
HPV status and localization of the tumour with different out-
come parameters. For every patient, the total nodal volume of all
lymph nodes, the largest axial diameter, the presence of necrosis
and ECS were correlated with clinical outcome.
In order to further investigate the prognostic signiﬁcance of the
presence of necrosis before or after treatment, patients were
assigned to four groups: (1) no necrosis on the pre- and post-CT
study, (2) necrosis on the pre-treatment study only, (3) necrosis
on post-treatment only and (4) necrosis on both the pre- and
post-treatment study. Pairwise comparisons between these
groups were made.
Figure 1. A flow diagram of patients included in the analysis.
HNC, head and neck cancer; CRT, chemoradiation; RT, radia-
tion therapy; CT, chemotherapy (ChT), study.
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A stepwise selection procedure was followed to construct
a multivariable prediction model for regional relapse within
3 years. The area under the receiver-operating characteristic
curve (AUC) was determined for the selected model. In addition
a bootstrap-corrected AUC value was calculated. This AUC value
corrects for overoptimism resulting from the fact that model
construction and model validation were performed on the same
data set.
HPV analysis
For all patients with oropharyngeal tumours, formalin-ﬁxed,
parafﬁn-embedded tissue was obtained for HPV status
Table 1. Patient and treatment characteristics
Characteristics Number of patients (%) (n5 183)
Mean age (years) 59
Sex
Male 155 85
Primary tumour site
Oral cavity 30 16
Oropharynx 122 67
HPV1 20
HPV2 92
Unknown HPV status 10
Hypopharynx 25 14
Larynx 6 3
T classiﬁcationa
T1 8 4
T2 47 26
T3 51 28
T4 76 42
N classiﬁcation
1 32 17
2 142 78
2a 7 4
2b 63 34
2c 72 39
3 9 5
Radiation therapy
3D CRT 84 46
IMRT 99 54
Systemic therapy
None 35 19
Cisplatin 118 64
Carboplatin/5-FU 2 1
Cetuximab 11 6
Panitumumab 8 4
Cisplatin1 tirapazamine 8 4
Cisplatin1 zalutumumab 1 1
3D CRT, three-dimensional conformal radiation therapy; 5-FU, 5-fluorouracil; IMRT, intensity-modulated radiation therapy.
aOne patient had four synchronous head and neck malignancies and was not included in the T classification statistics.
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determination. HPV testing was performed using p16 immu-
nohistochemistry followed by HPV polymerase chain reaction.
A tumour was regarded as HPV related when both p16 immu-
nohistochemistry as well as HPV polymerase chain reaction
were positive. Sections were scored as p16 positive when clear
p16 immunoreactivity was seen in at least 50% of cells.
RESULTS
Patient/treatment characteristics and outcome
We included 183 patients with head and neck cancer (Figure 1).
Patient and treatment characteristics are presented in Table 1.
Median follow-up was 5.04 years.
We report the following 3-year outcome rates: LC of 84% (95%
CI 77–88%), regional control (RC) of 80% (95% CI 73–86%)
MFS of 74% (95% CI 66–80%), DFS of 61% (95% CI 53–67%)
and OS of 63% (95% CI 56–70%).
A higher T stage was statistically signiﬁcantly associated with
a poorer LC (HR 1.570, p5 0.0316), RC at 2 years (OR 1.725,
p5 0.0346), DFS (HR 1.543, p5 0.0016) and OS (HR 1.364,
p5 0.0111). This was borderline signiﬁcant for MFS (HR 1.402,
p5 0.0523). Higher N stage was associated with a higher risk of
local relapse (HR 1.438, p5 0.0355). Age, gender, HPV status
and localization of primary tumour site could not be withheld as
useful predictors for outcome.
Results of the analysis of CT data
Pre-treatment CT study
On the pre-treatment CT study, 37 (20.2%) patients had ECS,
123 (67.2%) patients had necrosis and 3 (1.6%) patients had
calciﬁcations.
A trend was observed towards more RR when lymph node
necrosis was present pre-treatment (OR 2.4, p5 0.08). The
pre-treatment presence of necrosis was furthermore signiﬁcantly
associated with a higher risk of distant metastasis (HR 2.29,
p5 0.03). On the other hand, a higher total sum of nodal volume
was associated with a poorer DFS (HR 1.01, p5 0.01). There was
no impact of maximal nodal axial diameter, nor the presence of
calciﬁcations or ECS on outcome. Sensitivity, speciﬁcity, PPV and
NPV of the presence of necrosis and ECS for RR are presented in
Table 2. This was not conducted for the presence of calciﬁcations
because there was only one case in the analyzed subset of patients
with calciﬁcations present pre-treatment.
Post-treatment CT study
On the post-treatment CT study, 18 (10.7%) patients had ECS,
53 (31.6%) patients had necrosis and 21 (31.6%) patients had
calciﬁcations (31.6%).
Post-treatment, all predeﬁned characteristics (ECS, necrosis,
larger diameter and larger volume) except the presence of cal-
ciﬁcations were signiﬁcantly associated with poor outcome
(Table 3). Calciﬁcations post-treatment are thus correlated with
better outcome. Sensitivity, speciﬁcity, PPV and NPV for the
inﬂuence of necrosis, ECS and calciﬁcations on RR are presented
in Table 2.
The sum of nodal volumes showed a non-linear trend in relation
to the risk of distant metastasis (Figure 2a). Concerning OS,
a non-linear trend was observed for the maximal nodal diameter
(Figure 2b). Among all possible cut-off values for dichotomizing
the maximal nodal diameter, the value of 31.88mm provided the
best model ﬁt.
Presence of necrosis pre- vs post-treatment
The risk of RR signiﬁcantly increased in patients with post-
treatment necrosis only compared with patients without necrosis
(OR 13.50, p5 0.01), and for patients with pre- and post-
treatment necrosis compared with those with pre-treatment
necrosis only (OR 7.52, p5 0.01).
Development of a model to predict regional
recurrence
Based on our results, we developed a multivariable model for RR
prediction. After performing a stepwise selection procedure, pre-
treatment T stage (p5 0.02), post-treatment necrosis (p5 0.03)
and largest diameter (p5 0.01) were included in the model. The
AUC of this model was 0.78 (95% CI 0.633; 0.845); the bootstrap-
corrected AUC was 0.74 (95% CI 0.667; 0.889). The risk for RR
within 3 years can be calculated using following formula:
RR ð%Þ5 e
m
11 em
Table 2. Predictive value of CT characteristics for regional
recurrence (RR)
Characteristics
RR RR
Pre-CRT Post-CRT
Sensitivity (%)
Necrosis 81 65
ECS 16 23
Absence of calciﬁcations 90
Speciﬁcity (%)
Necrosis 36 77
ECS 81 92
Absence of calciﬁcations 14
PPV (%)
Necrosis 33 53
ECS 24 54
Absence of calciﬁcations 30
NPV (%)
Necrosis 83 84
ECS 72 75
Absence of calciﬁcations 79
CRT, chemoradiation; ECS, extracapsular spread; NPV, negative-predictive
value; PPV, positive-predictive value.
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m 5  0:085 3 largest axial diameter ðmmÞ
1 0:6749 3 ðT stageÞ 2 4:8482
1 ðonly when necrosisÞ 1:1384 :
DISCUSSION
The role of planned neck dissection after radio(chemo)therapy
for locoregionally advanced head and neck cancer has weak-
ened over the past decade but is still a matter of debate. Data
from mostly retrospective series support a conservative approach
with neck dissection (ND) carried out only in those patients with
residual disease on a clinical or radiological basis.12,15–20 Some
centres still perform planned neck dissection in all patients
with N2 or N3 disease, irrespective of their response to initial
treatment.21 Robust data from randomized trials addressing
this issue are lacking. In our centre, we advocate a conservative
approach, thereby avoiding neck dissection and its complica-
tions in a large amount of patients. Outcome in our patient
cohort is comparable with that described by other authors.
Liauw et al18 described a 5-year RC and OS of 84% and 45%,
respectively, in a group of 209 patients treated by radio(chemo)
therapy without neck dissection. Clavel et al17 reported a 3-year
RC and OS of 91% and 83%, respectively, in 369 patients
treated with radio(chemo)therapy and subsequent neck dis-
section in 96 patients.
The value of the pre-radiotherapy CT parameters is disputable.
In our data set, we could only conﬁrm a negative relation be-
tween the presence of necrosis and MFS, and between total
nodal volume and DFS. Moreover, we correlated clinical
parameters with outcome. A higher T stage was statistically
signiﬁcant associated with a poorer outcome.
In the post-treatment setting, scoring nodal CT characteristics
does have prognostic signiﬁcance. We conﬁrmed the value of
necrosis and ECS, as well as measuring lymph node diameter
and total nodal volume on CT studies after radio(chemo)therapy.
Within the range of the majority of the observations, a higher
lymph node volume leads to a higher risk for all outcome
parameters. Owing to a striking non-linear trend of largest nodal
axial diameter for OS, the variable was dichotomized, leading to
a cut-off at 31.88mm, above which OS is compromised more
importantly. A linear trend was observed for the relation between
nodal diameter and the other outcome parameters. Regarding
MFS, a non-linear trend was observed for the sum of nodal
Table 3. Predictive value of post-treatment CT characteristics for outcome
CT characteristic Outcome OR/HR (95% CI) p-value
+ nodal volume
RR OR 1.262 (1.072; 1.486) 0.0051
MFS Non-linear trend
DFS HR 1.051 (1.028; 1.074) ,0.0001
OS HR 1.056 (1.035; 1.078) ,0.0001
+ nodal volume 2 cm3 vs 1 cm3 MFS HR 1.152 (1.054; 1.259) 0.0018
Largest diameter
RR OR 1.108 (1.047; 1.172) 0.0004
MFS HR 1.043 (1.014; 1.072) 0.0036
DFS HR 1.059 (1.035; 1.083) ,0.0001
OS Non-linear trend ,0.0001
Largest diameter .31.8mm OS HR 5.764 (2.851; 11.651) ,0.0001
Necrosis
RR OR 5.960 (2.410; 14.738) 0.0001
MFS HR 2.203 (1.186; 4.092) 0.0124
DFS HR 2.668 (1.671; 4.262) ,0.0001
OS HR 2.406 (1.529; 3.785) 0.0001
Calciﬁcations
RR OR 0.643 (0.167; 2.483) 0.5189
MFS HR 0.950 (0.373; 2.421) 0.9143
DFS HR 0.843 (0.404; 1.759) 0.6494
OS HR 0.863 (0.430; 1.729) 0.6772
ECS
RR OR 3.451 (1.056; 11.283) 0.0404
MFS HR 2.482 (1.144; 5.385) 0.0214
DFS HR 2.343 (1.275; 4.303) 0.0061
OS HR 1.800 (0.971; 3.337) 0.0620
+, sum; CI, confidence interval; DFS, disease-free survival; ECS, extracapsular spread; HR, hazard ratio; MFS, metastasis-free survival; OR, odds ratio;
OS, overall survival; RR, regional recurrence.
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volumes in relation to the occurrence of distant metastasis.
Although, this non-linear trend was induced by a small number
of outlying values. In the lower range, where the majority of
observations lie, a linear relationship was seen.
We investigated the presence of pre- and post-treatment
necrosis further to see at which moment this parameter
was most predictive for RR. Patients with newly formed
necrosis have a higher risk of RR than patients without or
with pre-existing necrosis. The presence of the necrosis might
suggest more hypoxic nodal disease and might prevent
delivery of chemotherapy and reduce the effectiveness of
radiotherapy.
Using the results of our study, a model was constructed to es-
timate the risk for RR in a given patient. This model reached
a good AUC of 0.78. Because creation and validation of the
model was carried out in the same data set, we also calculated
a corrected AUC; this was 0.74. This corrected value gives an
honest estimate of the predictive accuracy of the model when
applied to an independent patient. For example, using our
model, a patient with a T4 tumour without necrotic pathological
lymph nodes and largest nodal axial diameter 12.1mm would
have a risk of 24.61% for developing an RR within 3 years.
To our knowledge, no other model using clinical parameters and
parameters obtained from a CT study or other imaging
modalities was proposed in other articles so far.
Figure 2. (a) The non-linear trend of sum of nodal volume in relation to risk of distant metastasis: the dots are representing
predictions for individual patients. (b) The non-linear trend of the largest nodal diameter in relation to overall survival: a best cut-off
for the largest axial diameter of 31.8mm was selected. The dots are representing predictions for individual patients.
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An extensive discussion of the role of other imaging modalities
of the neck after radio(chemo)therapy such as ultrasound, PET-
CT and MRI is beyond the scope of this article, but each of those
are believed to be useful in assessing response and the need for
salvage neck dissection. Ultrasound, in combination with ﬁne-
needle aspiration cytology, is an inexpensive and readily avail-
able tool. Yom et al22 described an NPV of 95% for ultrasound
ﬁne-needle aspiration cytology.23 Data on the role of post-
treatment PET-CT are emerging rapidly, and results are prom-
ising. Loo et al described an NPV of 100% for PET-CT obtained
3 months after completion of radiotherapy.15 This was further
investigated in a multicentre study (PET-NECK), which recruited
564 patients with N2 or N3 head and neck cancer treated with
radio(chemo)therapy and randomized between routine neck
dissection and a wait-and-see approach if PET-CT 9–13 weeks
after treatment shows no abnormal FDG-uptake in the neck.13
This study reports similar results in patients who underwent PET-
CT-guided surveillance and those who underwent planned neck
dissection, but surveillance resulted in fewer operations and was
more cost effective. In the last few years, advances in MRI, with
development of diffusion-weighted MR (DW-MRI) and dynamic
contrast-enhanced MRI, have provided additional information.
Recently, Vandecaveye et al24 evaluated response after radiother-
apy in 29 patients with DW-MRI at 3 weeks after completion of
treatment. He reported an NPVof 96% for adenopathies per neck
side, and a sensitivity of 78% of DW-MRI vs 67% for conven-
tional MRI for detecting subcentimetre lymph node metastasis.
We can conclude that CT is at least of equivalent value in the
assessment of the neck after radio(chemo)therapy. Moreover, CT
is more accessible than PET-CT and DW-MRI and has been
widely used for many years in this setting.
This was a monocentric retrospective study, with its inherent
limitations. However, we made sure to have sufﬁcient follow-up
of every patient in order to have ﬁrm reliable data. The strength
of this study lies in the large number of analyzed data and the
fact that all measurements were performed by the same observer,
with cooperation of both a radiation oncologist and a radiologist
specialized in head and neck cancer. This study can therefore be
a ﬁrst step in designing a prospective trial addressing the man-
agement of the neck post-radio(chemo)therapy and validating
the proposed model for RR prediction.
CONCLUSION
Our data conﬁrm that in a group of patients with locoregionally
advanced head and neck cancer, good disease control in the neck
can be obtained with radio(chemo)therapy without subsequent
planned neck dissection. Furthermore, we propose a multivari-
able model to calculate the risk of a regional relapse with an
AUC of 0.78 based on T stage before therapy and post-treatment
presence of necrosis and largest nodal diameter.
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